Current Report Filing (8-k)
March 28 2018 - 6:09AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) of the
SECURITIES
EXCHANGE ACT OF 1934
March
22, 2018
Date
of Report (Date of Earliest event reported)
PetLife
Pharmaceuticals, Inc.
(Exact
Name of Registrant as Specified in Charter)
Nevada
|
|
000-52445
|
|
33-1133537
|
(State
or other Jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
10120 So. Eastern Avenue, Suite 213, Henderson, NV 89052
|
(Address of principal executive offices)
|
Registrant’s telephone number, including area code:
|
(855) 682-7853
|
38
West Main St., Hancock, MD 21750
(Former
Name or Former Address, If Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13c-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (/Section
230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers
Effective March 22, 2018, Vyvyan Campbell
resigned as a Director of the Company. Ms. Campbell’s resignation was not the result of any disagreements with the Company
regarding our operations, policies, practices or otherwise. Also, on March 22, 2018, Ralph Salvagno, M.D., resigned as
Chief Executive Officer, President, Secretary, Treasurer, Chief Financial Officer, and Chairman of the Board of the Company.
Dr. Salvagno’s resignation was not the result of any disagreements with the Company regarding our operations, policies,
practices or otherwise. Concurrently, Laura De Leon Castro was appointed President, Chief Executive Officer, Secretary, Treasurer,
Chief Financial Officer, and Chairman of the Board of Directors of the Company.
Laura
De Leon Castro - Chief Executive Officer, President, Secretary, Treasurer, Principal Financial Officer, and Chairman of the Board
of Directors
Laura
De Leon Castro, age 43, was born and raised in the City of Monterrey, Mexico. She is a graduate of the law School of the University
of Monterrey. Following her graduation in 1996, she was employed as attorney with a law firm in Monterrey, Mexico from 1997 to
2000. Thereafter, she served as the Assistant to the Chief Executive Officer of Gatorade Mexico from 2001 to 2003. During that
period, she also became a certified Emergency Medical Technician. Following move to Spain in 2003, she has served as a volunteer
Emergency Medical Technician.
The
Company believes that Ms. De Leon Castro’s educational backgrounds and business and operational experiences give her the
qualifications and skills to serve as a Director and in her respective officer positions.
Ms.
De Leon Castro has not been involved in a transaction with related persons, promoters or control persons during the Company’s
preceding fiscal year.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Current Report on
Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
March 27, 2018
|
PETLIFE
PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/
Laura De Leon Castro
|
|
Name:
|
Laura
De Leon Castro
|
|
Title:
|
President
and Chief Executive Officer
|
Petlife Pharmaceuticals (CE) (USOTC:PTLF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Petlife Pharmaceuticals (CE) (USOTC:PTLF)
Historical Stock Chart
From Sep 2023 to Sep 2024